Chornenki NLJ, et al. - Because tranexamic acid (TXA) is known to reduce bleeding-related mortality in non-surgical settings, researchers assessed the impact of TXA use on thrombosis via conducting a systematic review and meta-analysis of 22 studies (n=49,538). They found that those who received TXA had a much lower risk of death from any cause. The risk of stroke, myocardial infarction, pulmonary embolism, or deep vein thrombosis from the use of TXA was not significantly increased. The outcomes were similar when limited to low-risk bias studies. They concluded that tranexamic acid use reduced all-cause mortality without increased risk of venous or thrombotic arterial complications.